Table 1.
Open in new tab

Dosing Recommendations for ZA in Pediatric Patients

DiagnosisInitial Dose, mg/kgSubsequent Doses, mg/kgMaximum Single DoseDosing Interval
Osteoporosis, low BMD for age0.01250.025–0.05<18 y, 4 mg; ≥18 y, 5 mg6–12 mo
AVN, CRMO, fibrous dysplasia0.01250.025–0.054 mg3–12 mo
OI and other genetic bone diseases0.0250.025–0.05<18 y, 4 mg; ≥18 y, 5 mg6–12 mo
Hypercalcemia of malignancy0.0250.025–0.054 mg1–6 wk
DiagnosisInitial Dose, mg/kgSubsequent Doses, mg/kgMaximum Single DoseDosing Interval
Osteoporosis, low BMD for age0.01250.025–0.05<18 y, 4 mg; ≥18 y, 5 mg6–12 mo
AVN, CRMO, fibrous dysplasia0.01250.025–0.054 mg3–12 mo
OI and other genetic bone diseases0.0250.025–0.05<18 y, 4 mg; ≥18 y, 5 mg6–12 mo
Hypercalcemia of malignancy0.0250.025–0.054 mg1–6 wk
Table 1.
Open in new tab

Dosing Recommendations for ZA in Pediatric Patients

DiagnosisInitial Dose, mg/kgSubsequent Doses, mg/kgMaximum Single DoseDosing Interval
Osteoporosis, low BMD for age0.01250.025–0.05<18 y, 4 mg; ≥18 y, 5 mg6–12 mo
AVN, CRMO, fibrous dysplasia0.01250.025–0.054 mg3–12 mo
OI and other genetic bone diseases0.0250.025–0.05<18 y, 4 mg; ≥18 y, 5 mg6–12 mo
Hypercalcemia of malignancy0.0250.025–0.054 mg1–6 wk
DiagnosisInitial Dose, mg/kgSubsequent Doses, mg/kgMaximum Single DoseDosing Interval
Osteoporosis, low BMD for age0.01250.025–0.05<18 y, 4 mg; ≥18 y, 5 mg6–12 mo
AVN, CRMO, fibrous dysplasia0.01250.025–0.054 mg3–12 mo
OI and other genetic bone diseases0.0250.025–0.05<18 y, 4 mg; ≥18 y, 5 mg6–12 mo
Hypercalcemia of malignancy0.0250.025–0.054 mg1–6 wk
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close